---
title: "Moderna's focus on cancer boosts stock by 177%, pivoting away from Covid-19 vaccine demand drop."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296465055.md"
description: "The company experienced a significant decline in its financial performance as demand for Covid-19 vaccines sharply dropped. Despite this setback, the company remained focused on developing another product or service."
datetime: "2026-08-20T09:08:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296465055.md)
  - [en](https://longbridge.com/en/news/296465055.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296465055.md)
generator: "portal-rs"
---

# Moderna's focus on cancer boosts stock by 177%, pivoting away from Covid-19 vaccine demand drop.

The company experienced a significant decline in its financial performance as demand for Covid-19 vaccines sharply dropped. Despite this setback, the company remained focused on developing another product or service.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)
- [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [REG - GraniteShares Fin. Graniteshares 3x S M Granite 3X shrt Mod£ - 3SMO - SOL3 - Early termination notice](https://longbridge.com/en/news/296371392.md)
- [BioNTech’s rally on Moderna trial win likely to fade, Leerink says](https://longbridge.com/en/news/296380155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**